Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 6/20 | 0.51 |
| ▸ | ADORA1 | P30542 | 6/20 | 0.51 |
| ▸ | ADORA2A | P29274 | 5/20 | 0.51 |
| ▸ | TSHR | P16473 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 3/20 | 0.41 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | DCTPP1 | Q9H773 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | BAZ2B | Q9UIF8 | 1/20 | 0.40 |
| ▸ | BAZ2A | Q9UIF9 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1268446 | 0.86 | ADORA3 (0.50) | ADORA3ADORA1ADORA2ATSHRMAPT | |
| SCHEMBL20028548 | 0.86 | TSHR (0.43) | ADORA3ADORA1ADORA2ATSHRMAPT | |
| SCHEMBL25298961 | 0.84 | ADORA3 (0.49) | ADORA3ADORA1ADORA2ATSHRMAPT | |
| SCHEMBL20098494 | 0.84 | ADORA3 (0.55) | ADORA3ADORA1ADORA2ATSHRMAPT | |
| SCHEMBL2671684 | 0.84 | ADORA3 (0.49) | ADORA3ADORA1ADORA2ATSHRMAPT | |
| SCHEMBL841373 | 0.83 | SMN1; SMN2 (0.39) | ADORA3ADORA1ADORA2AMAPTKDM4E | |
| SCHEMBL21963326 | 0.83 | ADORA3 (0.48) | ADORA3ADORA1ADORA2ATSHRNR1H2 | |
| SCHEMBL24978324 | 0.83 | ADORA3 (0.45) | ADORA3ADORA1ADORA2ATSHRMAPT | |
| SCHEMBL574351 | 0.81 | KDM4E (0.48) | ADORA3ADORA1ADORA2ATSHRKDM4E | |
| SCHEMBL2927479 | 0.80 | MAPK1 (0.59) | ADORA3ADORA1ADORA2ATSHRMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220259193-A1 | KCNT1 INHIBITORS AND METHODS OF USE | PRAXIS PRECISION MEDICINES, INC. (US) | 2022-08-18 | — | — | US | disclosed |
| EP-3962481-A1 | KCNT1 INHIBITORS AND METHODS OF USE | Praxis Precision Medicines, Inc. (US) | 2022-03-09 | — | — | EP | disclosed |
| WO-2020227101-A1 | KCNT1 INHIBITORS AND METHODS OF USE | PRAXIS PRECISION MEDICINES, INC. (US) | 2020-11-12 | — | — | WO | disclosed |
| EP-3087058-B1 | PROCESS FOR THE REGIOSELECTIVE SYNTHESIS OF PYRAZOLES | ISAGRO SPA (IT) | 2017-09-06 | — | — | EP | disclosed |
| EP-3087058-B1 | PROCESS FOR THE REGIOSELECTIVE SYNTHESIS OF PYRAZOLES | ISAGRO SPA (IT) | 2017-09-06 | — | — | EP | disclosed |
| US-9676726-B2 | Process for the regioselective synthesis of pyrazoles | ISAGRO S.P.A. (IT) | 2017-06-13 | — | — | US | disclosed |
| US-9676726-B2 | Process for the regioselective synthesis of pyrazoles | ISAGRO S.P.A. (IT) | 2017-06-13 | — | — | US | disclosed |
| US-9676726-B2 | Process for the regioselective synthesis of pyrazoles | ISAGRO S.P.A. (IT) | 2017-06-13 | — | — | US | disclosed |
| US-20160318874-A1 | PROCESS FOR THE REGIOSELECTIVE SYNTHESIS OF PYRAZOLES | FMC IP TECHNOLOGY GMBH (CH) | 2016-11-03 | — | — | US | disclosed |
| US-20160318874-A1 | PROCESS FOR THE REGIOSELECTIVE SYNTHESIS OF PYRAZOLES | FMC IP TECHNOLOGY GMBH (CH) | 2016-11-03 | — | — | US | disclosed |
| US-20160318874-A1 | PROCESS FOR THE REGIOSELECTIVE SYNTHESIS OF PYRAZOLES | FMC IP TECHNOLOGY GMBH (CH) | 2016-11-03 | — | — | US | disclosed |
| WO-2015097658-A1 | PROCESS FOR THE REGIOSELECTIVE SYNTHESIS OF PYRAZOLES | ISAGRO S.P.A. (IT) | 2015-07-02 | — | — | WO | disclosed |
| US-8143293-B2 | disease caused by c-Abl kinase, c-Kit kinase, oncogenic forms, aberrant fusion proteins and polymorphs; 1-(3-t-butylisoxazol-5-yl)-3-(2-fluoro-4-(2-(1-methyl-1H-pyrazol-4-yl)pyridin-4-yloxy)phenyl)urea | DECIPHERA PHARMACEUTICALS, LLC (US) | 2012-03-27 | — | — | US | disclosed |
| WO-2012019015-A2 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF MYELOPROLIFERATIVE DISEASES AND OTHER PROLIFERATIVE DISEASES | DECIPHERA PHARMACEUTICALS, LLC (US) | 2012-02-09 | — | — | WO | disclosed |
| US-20110189167-A1 | Methods and Compositions for the Treatment of Myeloproliferative Diseases and other Proliferative Diseases | DECIPHERA PHARMACEUTICALS, LLC | 2011-08-04 | — | — | US | disclosed |
| EP-2146716-A1 | KINASE INHIBITORS USEFUL FOR THE TREATMENT OF MYLEOPROLIFERATIVE DISEASES AND OTHER PROLIFERATIVE DISEASES | Deciphera Pharmaceuticals, LLC. (US) | 2010-01-27 | — | — | EP | disclosed |
| WO-2008131227-A1 | KINASE INHIBITORS USEFUL FOR THE TREATMENT OF MYLEOPROLIFERATIVE DISEASES AND OTHER PROLIFERATIVE DISEASES | DECIPHERA PHARMACEUTICALS, LLC (US) | 2008-10-30 | — | — | WO | disclosed |
| US-20080261965-A1 | KINASE INHIBITORS USEFUL FOR THE TREATMENT OF MYLEOPROLIFIC DISEASES AND OTHER PROLIFERATIVE DISEASES | DECIPHERA PHARMACEUTICALS, LLC (US) | 2008-10-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110189167-A1 | Methods and Compositions for the Treatment of Myeloproliferative Diseases and other Proliferative Diseases | MCL1, NRAS, ABL1 | ADORA3 4701/4885ADORA1 4769/4885ADORA2A 4138/4885 |
| US-20160318874-A1 | PROCESS FOR THE REGIOSELECTIVE SYNTHESIS OF PYRAZOLES | CYP4F11, CYP2F1, CYP3A4 | ADORA3 2924/4885ADORA1 2946/4885ADORA2A 3646/4885 |
| US-20080261965-A1 | KINASE INHIBITORS USEFUL FOR THE TREATMENT OF MYLEOPROLIFIC DISEASES AND OTHER PROLIFERATIVE DISEASES | KIT, PRKACA, BRAF | ADORA3 3605/4885ADORA1 4520/4885ADORA2A 3736/4885 |
| US-20220259193-A1 | KCNT1 INHIBITORS AND METHODS OF USE | KCNT1, KCNT2, KCNQ2 | ADORA3 1548/4885ADORA1 1376/4885ADORA2A 2022/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.